An Evaluation of the Effectiveness of Risk Minimization Measures for Tigecycline in the European Union
Crossref DOI link: https://doi.org/10.1007/s40290-017-0180-z
Published Online: 2017-02-22
Published Print: 2017-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Frajzyngier, Vera
Quintana, Alvaro
Tucker, Hal
Wible, Michele
Hickman, Anne
Baillon-Plot, Nathalie
Lundin, Rebecca
Montravers, Philippe
Bassetti, Matteo
Eckmann, Christian
Rottinghaus, Scott
Funding for this research was provided by:
Pfizer, Inc.
License valid from 2017-02-22